Loading
Life sciences · Review
Heliyon · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lung cancer is the No.1 malignant tumor with the highest morbidity and mortality in the world. The prognosis of lung cancer depends not only on the tumor itself and the treatment, but also on the nutritional and immune status of the patients. Nutritional status can affect the quality of life and response to therapy, while immune status can also affect the biological behavior of tumor spread and metastasis by changing the microenvironment. Abnormal nutrition and immune response can interact with each other to reduce body's response to anti-cancer treatment and promote tumor progression. In recent years, with the increasing attention to this field, a large number of tumor-related prognostic indicators have emerged based on inflammatory immune and nutrition-related tests such as prognostic nutritional indicators and immune inflammation indicators. Researchers attempted to use these composite indexes to comprehensively assess the prognosis of lung cancer patients and guide clinical treatment decisions. This review synthesizes recent studies on the prognostic value of nutrition and immunity indexes for lung cancer, so as to identify optimal indicators for clinical application for lung cancer patients to evaluate their prognosis after the therapies and to help doctors make better intervention strategies.